Trofinetide and NNZ-2591 publications    
Year Journal Authors Subject
2019 Neurology® 2019;92:e1912-e1925 Glaze et al Double-blind, ramdomized, placebo-controlled study of trofinetide in pediatric Rett syndrome
2017 Pediatric Neurology S0887-8994(17)30405-8 Glaze et al A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome
2017 Genes, Brain and Behavior 10.1111/gbb.12373 Deacon et al Nrf2, A Novel Therapeutic Target in Fragile X Syndrome is Modulated by NNZ-2566
2017 European Journal of Pharmaceutical Sciences 2017.05.032 Oosterholt et al Population pharmacokinetics of NNZ-2566 in healthy subjects
2015 Journal of Child Neurology 1-6 Neul et al Improving treatment trial outcomes for Rett syndrome: the development of Rett-specific anchors for the Clinical Global Impression Scale
2015 Neuromolecular Medicine 17: 71-82 Deacon et al NNZ-2566, a novel analog of (1–3) IGF-1, as a potential therapeutic agent for Fragile X syndrome
2013 NeuroMolecular Medicine 15 (3): 504-14 Cartagena et al Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3
2010 Behavioural Brain Research 210 (2010) 221-228 Guan et al NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat
2009 British Journal of Pharmacology (2009) 156, 662-672 Krishnamurthi et al A novel diketopiperazine improves functional recovery given after the onset of 6-OHDA-induced motor deficit in rats
2009 Journal of Neurotrauma 26: 141–154 Lu et al NNZ-2566, a glypromate analog, improves functional recovery and attenuates apoptosis and inflammation in a rat model of penetrating ballistic-type brain injury
2009 Journal of Cerebral Blood Flow & Metabolism 00: 1-9 Lu et al NNZ-2566, a glypromate analog, attenuates brain ischemia-induced nonconvulsive seizures in rats
2009 Journal of Neuroinflammation 6: 19-29 Wei et al NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats
2009 Journal of the Neurological Sciences 278 (1-2): 85-90 Bickerdike et al NNZ-2566: A Gly–Pro–Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke
2007 Developmental Neuroscience 29: 393-402 Svedin et al Delayed peripheral administration of a GPE analogue induces astrogliosis and angiogenesis and reduces inflammation and brain injury following hypoxia-ischemia in the neonatal rat
Other relevant publications    
Year Journal Authors Subject
2019 Molecular Psychiatry s41380-018-0325-9 Wang et al A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability
2014 Acta Neuropathologica 128: 333-345 Derecki et al Microglia as a critical player in both developmental and late-life CNS pathologies
2014 Scientific Reports 4 : 4388 Guan et al Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1
2013 Molecular Autism 4:9 Bozdagi et al IGF-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay
2013 Glia 61: 24-36 Schafer et al The Quad-partite synapse: microglia-synapse interactions in the developing and mature CNS
2013 Journal of Neuroinflammation 10:37 Suh et al IGF-1 and IGF-2 expression in human microglia differential regulation by inflammatory mediators
2012 Neuroscience Letters 520: 51-56 Corvin et al IGF1 and its active peptide (1–3)IGF1 enhance the expression of synaptic markers in neuronal circuits through different cellular mechanisms
2012 Neuropsychopharmacology 37: 1152-1163 De Filippis et al Modulation of RhoGTPases Improves the Behavioral Phenotype and Reverses Astrocytic Deficits in a Mouse Model of Rett Syndrome
2012 Nature 484 (7392): 105-109 Derecki et al Wild type microglia arrest pathology in a mouse model of Rett syndrome
2011 Neuron Glia Biology 7 (01): 85-97 Maezawa et al Does microglial dysfunction play a role in autism and Rett syndrome
2011 Nature 475 (7357): 497-500 Lioy et al A role for glia in the progression of Rett syndrome
2011 Human Molecular Genetics 20: 1182-1196 Ricciardi et al Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model
2010 Journal of Neuorscience 30 (15): 5346-5356 Maezawa et al Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate
2010 Current Psychiatric Reports 12: 127-134 Gonzales et al The role of MeCP2 in brain development and neurodevelopmental disorders
2009 PNAS 106: 2029-2034 Tropea et al Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice
2009 British Journal of Pharmacology (2009), 157, 881–891 Guan et al IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions
2007 Journal of Neuropathology and Experimental Neurology 66 (2): 117-123 Itoh et al Methyl CpG-Binding Protein 2 Directly Regulates Insulin-Like Growth Factor Binding Protein 3 in Mouse and Human Brains
2004 Journal of Pediatric Neurology 2(3): 143-146 Guideri et al Echocardiographic evaluation in Rett children with cardiac dysautonomia
2004 PNAS 101: 6033-6038 Luikenhuis et al Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice
2003 Human Molecular Genetics 12 R221-R227 Kriaucionis et al DNA methylation and Rett syndrome
2003 American Journal of Medical Genetics 122A: 227–233 Smeets et al Rett syndrome in adolescent and adult females: clinical and molecular genetic findings
2002 Neuron 35: 243–254 Shahbazian et al Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3
2001 Brain Research 922: 42-50 Sizonenko et al Neuroprotective effects of the N-terminal tripeptide of IGF-1, glycine-proline-glutamate, in the immature rat brain after hypoxic–ischemic injury
2001 American Journal of Medical Genetics 104: 14-22 Zappella et al Preserved speech variants of the Rett syndrome molecular and clinical analysis
1999 NeuroReport 10: 161-164 Saura et al Neuroprotective effects of Gly-Pro-Glu, the Nterminal tripeptide of IGF-1, in the hippocampus in vitro
1999 Nature Genetics 23: 183 188 Amir et al Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
1995 Neuron 14: 717-730 Beck et al IGF-1 gene disruption results in reduced brain size, CNS hypomyelination, and loss of hippocampal granule and striatial parvalbumin-containing neurons
1993 Annals New York Academy of Sciences 183-191 Sara et al The Biological Role of Truncated Insulin-like Growth Factor-1 and the Tripeptide GPE in the Central Nervous System
1989 Biochemical and Biophysical Research Communications 165, 2, 766-771 Sara et al Identification of gly-pro-glu (gpe), the aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide